tradingkey.logo

Insulet Corp

PODD
View Detailed Chart
311.950USD
-4.220-1.33%
Close 10/30, 16:00ETQuotes delayed by 15 min
21.96BMarket Cap
93.00P/E TTM

Insulet Corp

311.950
-4.220-1.33%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.33%

5 Days

-5.25%

1 Month

+0.43%

6 Months

+24.15%

Year to Date

+19.49%

1 Year

+34.25%

View Detailed Chart

TradingKey Stock Score of Insulet Corp

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Insulet Corp's Score

Industry at a Glance

Industry Ranking
33 / 210
Overall Ranking
104 / 4623
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 27 analysts
Buy
Current Rating
360.556
Target Price
+11.17%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Insulet Corp Highlights

StrengthsRisks
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.71% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.07B.
Fairly Valued
The company’s latest PE is 94.01, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 71.86M shares, decreasing 4.80% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 2.14M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Insulet Corp Info

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.
Ticker SymbolPODD
CompanyInsulet Corp
CEOMs. Ashley Mcevoy
Websitehttps://www.omnipod.com
KeyAI